Qiagen secures U.S. clearance for QIAstat-Dx mini gastrointestinal panel

QIAGEN (QGEN) announced the U.S. regulatory clearance of the first in a series of QIAstat-Dx Gastrointestinal Panel tests for clinical use. This clearance by the U.S. Food and Drug Administration marks the second mini syndromic panel in the U.S. and made available for use with QIAstat-Dx systems, supporting QIAGEN’s strategy to improve patient treatment options in this important market.